Smile Doctors and Dental Monitoring Expand and Accelerate Partnership to Provide Remote Monitoring to All Patients During the State of Emergency
Smile Doctors, the largest US based Orthodontic DSO (Dental Support Organization), with over 220 locations in 17 States, has signed a deal with Dental Monitoring to use its suite of AI powered remote monitoring solutions to provide industry leading patient access and convenience. Importantly, the original partnership agreed after several months of pilots and testing, has been expanded and accelerated to include all patients eligible with immediate effect this week, due to the Coronavirus national situation. All eligible Smile Doctors patients will therefore be able to start or continue their treatment remotely with Dental Monitoring.
Dental Monitoring will provide access to and training for all Smile Doctors specialist orthodontist clinics nationwide to all DM products, including SmileMate, Vision and Dental Monitoring.
- SmileMate enables virtual consultations with prospective new patients at home, offering an almost instant oral health assessment through photos taken with the patient’s own smartphone.
- Vision uses AI to produce within seconds an instant simulation of the patient’s face with different orthodontic appliances and also generates state-of-the-art simulation of post-treatment smiles, using the actual details of the patient’s teeth and gums, helping the patient choose their treatment with more confidence.
- Dental Monitoring uses AI to allow the Doctor to remotely monitor the progress of the patient’s treatment through photos taken by the patient using the DM app on their own smartphone, with a DM ScanBox. The Dental Monitoring solution allows real time communication between the Doctor’s team and the patient.
Commenting on the deal, CEO of Smile Doctors, J. Hedrick explained: “I am delighted to have achieved this partnership with Dental Monitoring, which I am certain will be to the extreme benefit to all of our patients. Dental Monitoring’s AI technology and patient user experience is second to none, and has brought dentistry up to speed with patients’ expectations in a digital world. The initial reception by both clinical team and patients in our pilots has been extremely positive, and we believe we have a unique differentiator in our offering to our Smile Doctors patients.”
CEO and Co-Founder of Dental Monitoring, Philippe Salah, added: “Smile Doctors for us is the ideal partner as we accelerate our growth in the US. We have established a true partnership where we will help Smile Doctors to fully utilize the full suite of DM products. We enable their orthodontists to address the needs of new patients, allow more of them to say yes to treatment, and then monitor their treatment progress efficiently, using our DM proprietary AI engine.”
On the acceleration of the partnership due to the current Coronavirus crisis, J. Hedrick said: “We decided to fast track our implementation of DM full heartedly throughout our entire network to make sure we could continue to serve our patients with the best clinical care. Dental Monitoring has been a unique and essential partner for us, and we are excited to be rolling out this service at such speed to respond to the crisis. I am grateful to Philippe and the DM team for really working side by side with us on this 24/7 in the interests of our patients.”
About Dental Monitoring (www.dental-monitoring.com)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney. For more information, please visit www.dental-monitoring.com.
About Smile Doctors, LLC ( www.smiledoctors.com )
Smile Doctors, LLC is the largest orthodontic dental support organization with more than 200 affiliated practices in 17 states. Based in Georgetown, TX and founded by Dr. Scott Law, Scotte Hudsmith, Dr. Dana Fender, and Dr. Greg Goggans, Smile Doctors focuses exclusively on developing and growing affiliated orthodontic practices. Orthodontists can focus on patient care while receiving the support of experienced professionals who are committed to the growth and success of their practices. Support provided by Smile Doctors includes services related to operations, accounting, marketing, and revenue cycle. For more information, please visit www.smiledoctors.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200320005353/en/
Contact information
Contact Dental Monitoring: Charlotte Garzino c.garzino@dental-monitoring.com
Contact SmileDoctor: Jessica Lynch, VP Operations - Jessica.Lynch@smiledoctors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom